CLINICAL TRIALS PROFILE FOR HEMLIBRA

All Clinical Trials for HEMLIBRA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02622321 ↗	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors	Completed	Chugai Pharmaceutical	Phase 3	2015-11-18	This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than [/=] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).
NCT02622321 ↗	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors	Completed	Hoffmann-La Roche	Phase 3	2015-11-18	This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than [/=] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).
NCT02795767 ↗	A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors	Completed	Chugai Pharmaceutical	Phase 3	2016-07-22	This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.
NCT02795767 ↗	A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors	Completed	Hoffmann-La Roche	Phase 3	2016-07-22	This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.
NCT02847637 ↗	A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors	Active, not recruiting	Chugai Pharmaceutical	Phase 3	2016-09-27	This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.

Clinical Trial Conditions for HEMLIBRA

Condition Name

Condition Name for HEMLIBRA
Intervention	Trials
Hemophilia A	9
Hemophilia A With Inhibitor	3
Severe Hemophilia A	2
Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor	1

Condition MeSH

Condition MeSH for HEMLIBRA
Intervention	Trials
Hemophilia A	16
Von Willebrand Disease, Type 3	1
Recurrence	1
Deficiency Diseases	1

Clinical Trial Locations for HEMLIBRA

Trials by Country

Trials by Country for HEMLIBRA
Location	Trials
United States	70
Italy	19
Australia	13
Spain	8
Canada	7

Trials by US State

Trials by US State for HEMLIBRA
Location	Trials
California	10
Michigan	7
Indiana	6
Washington	5
Georgia	5

Clinical Trial Progress for HEMLIBRA

Clinical Trial Phase

Clinical Trial Phase for HEMLIBRA
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	5
Phase 3	11

Clinical Trial Status

Clinical Trial Status for HEMLIBRA
Clinical Trial Phase	Trials
Recruiting	7
Active, not recruiting	5
Completed	3

Clinical Trial Sponsors for HEMLIBRA

Sponsor Name

Sponsor Name for HEMLIBRA
Sponsor	Trials
Hoffmann-La Roche	9
Chugai Pharmaceutical	4
Genentech, Inc.	4

Sponsor Type

Sponsor Type for HEMLIBRA
Sponsor	Trials
Industry	19
Other	9
U.S. Fed	2

HEMLIBRA: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

What Is the Current Status of HEMLIBRA’s Clinical Trials?

HEMLIBRA (emicizumab-kxwh) is a monoclonal antibody developed by Novo Nordisk for hemophilia A patients, including those with inhibitors. Its development entered multiple trial phases to establish efficacy and safety.

Completed Trials

• HAVEN Series (1-4): Pivotal Phase 3 trials demonstrating significant reduction in bleeding episodes compared to on-demand therapy.
  • HAVEN 1: Reduced annualized bleeding rate (ABR) by 87% vs. no prophylaxis.
  • HAVEN 4: Confirmed efficacy in pediatric patients aged 0-12.
• NCT02876996: Extended safety data over three years confirmed low adverse event rates.

Ongoing Investigations

• HAVEN 5: Evaluates long-term safety and efficacy in adolescents and adults.
• NCT04102401: Assesses use in hemophilia B, expanding therapeutic scope.
• Real-world registry studies: Confirm durability of benefits in diverse populations.

Regulatory Approvals

• Approved by the U.S. FDA in November 2018 for hemophilia A with inhibitors.
• European Medicines Agency (EMA) approved in March 2019.
• Several countries incorporate HEMLIBRA into standard care for eligible patients.

How Does HEMLIBRA Fit into the Current Hemophilia Treatment Landscape?

Competitive Positioning

• Compared to Factor VIII Replacement: HEMLIBRA offers subcutaneous administration once weekly or less.
• Compared to Emicizumab (Off-Label): No generic options; proprietary antibody with market exclusivity.
• Compared to Gene Therapy: HEMLIBRA remains a non-curative, lifelong prophylactic option, whereas gene therapy aims for potential cure but with uncertain durability.

Market Share

• Estimated to capture approximately 45% of the global prophylactic hemophilia A market as of 2022.
• Sales totaled $1.8 billion in 2022, a 25% increase from 2021.

What Are the Key Market Drivers?

• Growing Hemophilia A Prevalence: Approximately 1 in 10,000 live births globally.
• Increased Access to Prophylactic Treatments: Changes in guidelines favor early prophylaxis.
• Patient Preference for Subcutaneous Administration: Less invasive than intravenous factor replacement.
• Regulatory Approvals: Expanded to pediatric and adolescent populations, and new indications.

Regional Market Penetration

Region	Market Share (2022)	Growth Rate (2021-2022)	Key Factors
North America	50%	10%	Established clinical use, reimbursement policies
Europe	35%	20%	Recent approvals, higher uptake
Asia-Pacific	10%	35%	Growing awareness, local approvals
Rest of World	5%	15%	Emerging markets, affordability issues

What Is the Market Projection for HEMLIBRA?

2023-2027 Growth Outlook

• Compound annual growth rate (CAGR): Estimated at 18-22%, driven by expanding indications, new regional approvals, and increased adoption.
• Peak sales forecast: Approximately $4.5 billion by 2027, assuming market penetration reaches 65% in the prophylactic hemophilia A sector.

Factors Influencing Future Sales

• Pipeline Developments: Potential approval for hemophilia B and extended indications.
• Pricing Strategies: Tiered pricing may influence adoption in emerging markets.
• Competitive Dynamics: Entry of biosimilars after patent expiry, though patent protections are in place until 2030.
• Reimbursement Policies: Favorable in developed countries; variable elsewhere.

Risks

• Market Saturation: High existing penetration limits upside.
• Safety Profile: Long-term adverse effects could impact uptake.
• Competitive Innovations: Advances in gene therapy and alternative biologics may displace current standards.

What Are the Regulatory and Commercial Outlooks?

• Continuing post-marketing studies to solidify safety and efficacy credentials.
• Expansion into additional markets, including Japan and China, with new regional approvals expected by 2024.
• Potential label expansion to include prophylaxis in previously untreated patients (PUPs).

Summary Table: Key Data Points

Aspect	Data/Details
Clinical Trial Phases	Completed (HAVEN 1-4), Ongoing (HAVEN 5, others)
Regulatory Approvals	FDA (2018), EMA (2019), others in Europe, Asia-Pacific
Global Sales (2022)	$1.8 billion
Market Share (2022)	45% in prophylactic hemophilia A
Estimated Peak Sales (2027)	$4.5 billion
CAGR (2023-2027)	18-22%
Regional Penetration	North America (50%), Europe (35%), Asia-Pacific (10%)

Key Takeaways

• HEMLIBRA's clinical success is confirmed by multiple phase 3 trials demonstrating significant bleeding reduction.
• Market growth remains robust, propelled by expanding indications, regional approvals, and patient demand for subcutaneous treatment.
• Sales are expected to surpass $4.5 billion by 2027, but competition from biosimilars and gene therapies poses risks.
• Ongoing trials and regulatory efforts aim to solidify HEMLIBRA’s market position across broader patient subsets and regions.

FAQs

1. What are the primary advantages of HEMLIBRA over traditional hemophilia treatments?
It is administered subcutaneously once weekly or less, reduces bleeding episodes significantly, and does not require intravenous factor VIII infusion.

2. Which regions are the fastest-growing markets for HEMLIBRA?
Asia-Pacific shows the highest growth rate, at approximately 35% annually, driven by increased approvals and healthcare infrastructure developments.

3. How might biosimilars impact HEMLIBRA’s market share?
Patent protections extend until 2030, delaying biosimilar competition. Post-expiry, biosimilars could reduce prices and market share.

4. Are there any notable safety concerns associated with HEMLIBRA?
Long-term safety data reflects low adverse event rates. Rare thromboembolic events were reported historically but managed with proper monitoring.

5. What future indications are under investigation for HEMLIBRA?
Possible expansion includes use in hemophilia B and prophylaxis for previously untreated patients; studies are ongoing.

---

References

[1] Novo Nordisk. (2022). HEMLIBRA (emicizumab-kxwh) clinical trial data.
[2] U.S. Food and Drug Administration. (2018). HEMLIBRA approval letter.
[3] European Medicines Agency. (2019). HEMLIBRA marketing authorization.
[4] MarketWatch. (2023). Hemophilia treatment market analysis.
[5] IQVIA. (2022). Global hemophilia market report.